tiprankstipranks
Telix Pharmaceuticals Ltd. (TLPPF)
OTHER OTC:TLPPF
US Market
TLPPF
Telix Pharmaceuticals
RESEARCH TOOLSreports

Telix Pharmaceuticals (TLPPF) Stock Forecast & Price Target

181 Followers
See the Price Targets and Ratings of:

TLPPF Analyst Ratings

Strong Buy
8Ratings
Strong Buy
8 Buy
0 Hold
0 Sell
Based on 8 analysts giving stock ratings to
Telix
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

TLPPF Stock 12 Month Forecast

Average Price Target

$18.06
▲(72.02% Upside)
Based on 8 Wall Street analysts offering 12 month price targets for Telix Pharmaceuticals in the last 3 months. The average price target is $18.06 with a high forecast of $22.94 and a low forecast of $12.90. The average price target represents a 72.02% change from the last price of $10.50.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","14":"$14","23":"$23","9.5":"$9.5","18.5":"$18.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":22.93552,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$22.94</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18.061722000000003,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$18.06</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12.90123,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$12.90</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,9.5,14,18.5,23],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2025","6":"Nov<br/>2025","9":"Feb<br/>2026","12":"May<br/>2026","25":"May<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.5,11.456578461538461,12.413156923076922,13.369735384615385,14.326313846153846,15.282892307692308,16.23947076923077,17.196049230769233,18.152627692307693,19.109206153846152,20.065784615384615,21.022363076923078,21.97894153846154,{"y":22.93552,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.5,11.081670923076924,11.663341846153847,12.24501276923077,12.826683692307693,13.408354615384617,13.990025538461541,14.571696461538464,15.153367384615386,15.73503830769231,16.316709230769234,16.898380153846155,17.480051076923083,{"y":18.061722000000003,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.5,10.68471,10.86942,11.05413,11.23884,11.42355,11.60826,11.79297,11.97768,12.16239,12.3471,12.53181,12.71652,{"y":12.90123,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":17.87,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.53,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.08,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.05,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.2,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.36,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.25,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.39,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.58,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.23,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.53,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.85,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.5,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$22.94Average Price Target$18.06Lowest Price Target$12.90
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Canaccord Genuity Analyst forecast on TLPPF
Shane Storey
Canaccord Genuity
Canaccord Genuity
$21.5
Buy
104.78%
Upside
Reiterated
05/25/26
Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (NASDAQ: SMMT) and Telix Pharmaceuticals (Other OTC: TLPPF)
Morgan Stanley Analyst forecast on TLPPF
David Bailey
Morgan Stanley
Morgan Stanley
$16.05
Buy
52.90%
Upside
Reiterated
05/24/26
Analyst Reiterates Buy on Telix Pharmaceuticals, Sees 38–42% Upside with Unchanged $22.4 Price Target
Bell Potter Analyst forecast on TLPPF
John Hester
Bell Potter
Bell Potter
$13.62
Buy
29.69%
Upside
Reiterated
05/08/26
Analysts Offer Insights on Healthcare Companies: 10x Genomics (NASDAQ: TXG) and Telix Pharmaceuticals (Other OTC: TLPPF)
Citi Analyst forecast on TLPPF
Laura Sutcliffe
Citi
Citi
$22.94
Buy
118.43%
Upside
Reiterated
04/29/26
Analysts Are Bullish on These Healthcare Stocks: Telix Pharmaceuticals (TLPPF), NeoGenomics (NEO)
Jefferies Analyst forecast on TLPPF
David Stanton
Jefferies
Jefferies
$17.42→$19.64
Buy
87.03%
Upside
Reiterated
04/15/26
Analysts Offer Insights on Healthcare Companies: AbCellera Biologics (NASDAQ: ABCL), Telix Pharmaceuticals (Other OTC: TLPPF) and Johnson & Johnson (NYSE: JNJ)
RBC Capital Analyst forecast on TLPPF
Craig Wong-Pan
RBC Capital
RBC Capital
$12.9
Buy
22.87%
Upside
Reiterated
04/15/26
Analysts Are Bullish on These Healthcare Stocks: Telix Pharmaceuticals (TLPPF), Medline (MDLN)
UBS Analyst forecast on TLPPF
David Dai
UBS
UBS
$22.22
Buy
111.61%
Upside
Reiterated
04/08/26
Telix Pharmaceuticals (TLPPF) Gets a Buy from UBS
Jarden Analyst forecast on TLPPF
Steven Wheen
Jarden
Jarden
$15.05→$15.62
Buy
48.81%
Upside
Reiterated
04/07/26
Jarden Sticks to Their Buy Rating for Telix Pharmaceuticals (TLPPF)
TD Cowen Analyst forecast on TLPPF
Tara Bancroft
TD Cowen
TD Cowen
$14.33
Buy
36.52%
Upside
Reiterated
02/19/26
Telix: Dual-Product PSMA Strategy and Cash-Generating Diagnostics Base Support Buy Rating and Multibillion-Dollar Therapeutics Upside
Ord Minnett Analyst forecast on TLPPF
Unknown Analyst
Ord Minnett
Not Ranked
Ord Minnett
$16.2
Buy
54.27%
Upside
Reiterated
10/15/25
Telix Pharmaceuticals (TLPPF) Gets a Buy from Ord Minnett
CLSA Analyst forecast on TLPPF
Andrew Paine
CLSA
CLSA
$17.38
Buy
65.53%
Upside
Reiterated
10/03/25
CLSA Reaffirms Their Buy Rating on Telix Pharmaceuticals (TLPPF)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Canaccord Genuity Analyst forecast on TLPPF
Shane Storey
Canaccord Genuity
Canaccord Genuity
$21.5
Buy
104.78%
Upside
Reiterated
05/25/26
Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (NASDAQ: SMMT) and Telix Pharmaceuticals (Other OTC: TLPPF)
Morgan Stanley Analyst forecast on TLPPF
David Bailey
Morgan Stanley
Morgan Stanley
$16.05
Buy
52.90%
Upside
Reiterated
05/24/26
Analyst Reiterates Buy on Telix Pharmaceuticals, Sees 38–42% Upside with Unchanged $22.4 Price Target
Bell Potter Analyst forecast on TLPPF
John Hester
Bell Potter
Bell Potter
$13.62
Buy
29.69%
Upside
Reiterated
05/08/26
Analysts Offer Insights on Healthcare Companies: 10x Genomics (NASDAQ: TXG) and Telix Pharmaceuticals (Other OTC: TLPPF)
Citi Analyst forecast on TLPPF
Laura Sutcliffe
Citi
Citi
$22.94
Buy
118.43%
Upside
Reiterated
04/29/26
Analysts Are Bullish on These Healthcare Stocks: Telix Pharmaceuticals (TLPPF), NeoGenomics (NEO)
Jefferies Analyst forecast on TLPPF
David Stanton
Jefferies
Jefferies
$17.42→$19.64
Buy
87.03%
Upside
Reiterated
04/15/26
Analysts Offer Insights on Healthcare Companies: AbCellera Biologics (NASDAQ: ABCL), Telix Pharmaceuticals (Other OTC: TLPPF) and Johnson & Johnson (NYSE: JNJ)
RBC Capital Analyst forecast on TLPPF
Craig Wong-Pan
RBC Capital
RBC Capital
$12.9
Buy
22.87%
Upside
Reiterated
04/15/26
Analysts Are Bullish on These Healthcare Stocks: Telix Pharmaceuticals (TLPPF), Medline (MDLN)
UBS Analyst forecast on TLPPF
David Dai
UBS
UBS
$22.22
Buy
111.61%
Upside
Reiterated
04/08/26
Telix Pharmaceuticals (TLPPF) Gets a Buy from UBS
Jarden Analyst forecast on TLPPF
Steven Wheen
Jarden
Jarden
$15.05→$15.62
Buy
48.81%
Upside
Reiterated
04/07/26
Jarden Sticks to Their Buy Rating for Telix Pharmaceuticals (TLPPF)
TD Cowen Analyst forecast on TLPPF
Tara Bancroft
TD Cowen
TD Cowen
$14.33
Buy
36.52%
Upside
Reiterated
02/19/26
Telix: Dual-Product PSMA Strategy and Cash-Generating Diagnostics Base Support Buy Rating and Multibillion-Dollar Therapeutics Upside
Ord Minnett Analyst forecast on TLPPF
Unknown Analyst
Ord Minnett
Not Ranked
Ord Minnett
$16.2
Buy
54.27%
Upside
Reiterated
10/15/25
Telix Pharmaceuticals (TLPPF) Gets a Buy from Ord Minnett
CLSA Analyst forecast on TLPPF
Andrew Paine
CLSA
CLSA
$17.38
Buy
65.53%
Upside
Reiterated
10/03/25
CLSA Reaffirms Their Buy Rating on Telix Pharmaceuticals (TLPPF)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Telix Pharmaceuticals

3 Months
David StantonJefferies
Success Rate
13/18 ratings generated profit
72%
Average Return
+23.54%
Copying David Stanton's trades and holding each position for 3 Months would result in 72.22% of your transactions generating a profit, with an average return of +23.54% per trade.
1 Year
Steven WheenJarden
Success Rate
19/25 ratings generated profit
76%
Average Return
+46.44%
Copying Steven Wheen's trades and holding each position for 1 Year would result in 76.00% of your transactions generating a profit, with an average return of +46.44% per trade.
2 Years
Steven WheenJarden
Success Rate
16/25 ratings generated profit
64%
Average Return
+87.66%
Copying Steven Wheen's trades and holding each position for 2 Years would result in 64.00% of your transactions generating a profit, with an average return of +87.66% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

TLPPF Analyst Recommendation Trends

Rating
Jan 26
Feb 26
Mar 26
Apr 26
May 26
Strong Buy
18
25
31
31
24
Buy
0
1
1
4
5
Hold
1
1
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
19
27
32
35
29
In the current month, TLPPF has received 29 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. TLPPF average Analyst price target in the past 3 months is 18.06.
Each month's total comprises the sum of three months' worth of ratings.

TLPPF Financial Forecast

TLPPF Earnings Forecast

Next quarter’s earnings estimate for TLPPF is $0.02 with a range of $0.02 to $0.02. The previous quarter’s EPS was -$0.01. TLPPF beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year TLPPF has Performed in-line its overall industry.
Next quarter’s earnings estimate for TLPPF is $0.02 with a range of $0.02 to $0.02. The previous quarter’s EPS was -$0.01. TLPPF beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year TLPPF has Performed in-line its overall industry.

TLPPF Sales Forecast

Next quarter’s sales forecast for TLPPF is $236.07M with a range of $233.00M to $238.00M. The previous quarter’s sales results were $446.64M. TLPPF beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year TLPPF has Performed in-line its overall industry.
Next quarter’s sales forecast for TLPPF is $236.07M with a range of $233.00M to $238.00M. The previous quarter’s sales results were $446.64M. TLPPF beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year TLPPF has Performed in-line its overall industry.

TLPPF Stock Forecast FAQ

What is TLPPF’s average 12-month price target, according to analysts?
Based on analyst ratings, Telix Pharmaceuticals Ltd.’s 12-month average price target is 18.06.
    What is TLPPF’s upside potential, based on the analysts’ average price target?
    Telix Pharmaceuticals Ltd. has 72.02% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is TLPPF a Buy, Sell or Hold?
          Telix Pharmaceuticals Ltd. has a consensus rating of Strong Buy which is based on 8 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Telix Pharmaceuticals Ltd.’s price target?
            The average price target for Telix Pharmaceuticals Ltd. is 18.06. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $22.94 ,the lowest forecast is $12.90. The average price target represents 72.02% Increase from the current price of $10.5.
              What do analysts say about Telix Pharmaceuticals Ltd.?
              Telix Pharmaceuticals Ltd.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.
                How can I buy shares of TLPPF?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.